Positive clinical trial results for its second drug for Duchenne muscular dystrophy are lifting the stock. See why shares can move "significantly higher."
Positive clinical trial results for its second drug for Duchenne muscular dystrophy are lifting the stock. See why shares can move "significantly higher."
Share this Article
Comment on this Article
Recommended
Please to comment